DEK and acute myeloid leukemia: Lastly, the clinical application of menin inhibitors is gradually expanding to include other acute leukemia subtypes characterized by MEIS1-HOXA axis activation, such as specific AML subgroups with particularly poor prognosis like NUP98-r, DEK-NUP21, and UBTF-TD.